1. All Articles

    1-24 of 2798 1 2 3 4 ... 115 116 117 »
    1. Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

      Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

      Oncoimmunology. 2017;6(11):e1358331

      Authors: Cheung IY, Kushner BH, Modak S, Basu EM, Roberts SS, Cheung NV

      Read Full Article
      Mentions: Antibody
    2. Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.

      Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.

      Pediatr Hematol Oncol. 2017 Nov 17;:1-12

      Authors: Berthold F, Hömberg M, Proleskovskaya I, Mazanek P, Belogurova M, Ernst A, Sterba J

      Read Full Article
      Mentions: Treatment MYCN
    3. Gene expression and molecular pathway activation signatures of MYCN-amplified neuroblastomas.

      Gene expression and molecular pathway activation signatures of MYCN-amplified neuroblastomas.

      Oncotarget. 2017 Oct 13;8(48):83768-83780

      Authors: Petrov I, Suntsova M, Ilnitskaya E, Roumiantsev S, Sorokin M, Garazha A, Spirin P, Lebedev T, Gaifullin N, Larin S, Kovalchuk O, Konovalov D, Prassolov V, Roumiantsev A, Buzdin A

      Read Full Article
      Mentions: MYCN
    4. Elevated TIMP-1 expression is associated with a prometastatic phenotype, disease relapse, and poor survival in neuroblastoma.

      Elevated TIMP-1 expression is associated with a prometastatic phenotype, disease relapse, and poor survival in neuroblastoma.

      Oncotarget. 2017 Oct 10;8(47):82609-82620

      Authors: Paul P, Rellinger EJ, Qiao J, Lee S, Volny N, Padmanabhan C, Romain CV, Mobley B, Correa H, Chung DH

      Read Full Article
      Mentions: Relapse MYCN
    5. Radical Surgery Improves Survival in Patients with Stage 4 Neuroblastoma.

      Radical Surgery Improves Survival in Patients with Stage 4 Neuroblastoma.

      World J Surg. 2017 Nov 10;:

      Authors: Vollmer K, Gfroerer S, Theilen TM, Bochennek K, Klingebiel T, Rolle U, Fiegel H

      Abstract BACKGROUND: Neuroblastoma (NBL) is the most common extracranial solid tumor in children. Despite a good overall prognosis in NBL patients, the outcome of children with stage 4 disease, even with multimodal intensive therapy, remains poor.

      Read Full Article
      Mentions: Surgery
    6. PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO.

      PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO.

      Oncoimmunology. 2017;6(10):e1343775

      Authors: Siebert N, Zumpe M, Jüttner M, Troschke-Meurer S, Lode HN

      Abstract Immunotherapy with anti-GD2 antibody (Ab) ch14.18/CHO is effective for treatment of high-risk neuroblastoma (NB) patients and is mainly based on GD2-specific Ab-dependent cellular cytotoxicity (ADCC).

      Read Full Article
    7. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.

      Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.

      MAbs. 2017 Nov 09;:0

      Authors: Mueller I, Ehlert K, Endres S, Pill L, Siebert N, Kietz S, Brock P, Garaventa A, Valteau-Couanet D, Janzek E, Hosten N, Zinke A, Barthlen W, Varol E, Loibner H, Ladenstein R, Lode HN

      Read Full Article
    8. Immunohistochemical analysis of PDK1, PHD3 and HIF-1α expression defines the hypoxic status of neuroblastoma tumors.

      Immunohistochemical analysis of PDK1, PHD3 and HIF-1α expression defines the hypoxic status of neuroblastoma tumors.

      PLoS One. 2017;12(11):e0187206

      Authors: Ognibene M, Cangelosi D, Morini M, Segalerba D, Bosco MC, Sementa AR, Eva A, Varesio L

      Abstract Neuroblastoma (NB) is the most common solid tumor during infancy and the first cause of death among the preschool age diseases.

      Read Full Article
    9. MicroRNA profiles in neuroblastoma: Differences in risk and histology groups.

      MicroRNA profiles in neuroblastoma: Differences in risk and histology groups.

      Asia Pac J Clin Oncol. 2017 Nov 08;:

      Authors: Ergin K, Aktaş S, Altun Z, Dınız G, Olgun N

      Abstract AIM: To determine the miRNA expression profiles of neuroblastomas with different clinical and histological characteristics. METHODS: In this study 24 samples from 17 patients, paraffin blocks were used.

      Read Full Article
    10. PRecISion Medicine for Children With Cancer

      PRecISion Medicine for Children With Cancer

      Conditions :   Childhood Cancer;   Childhood Solid Tumor;   Childhood Brain Tumor;   Childhood Leukemia;   Refractory Cancer;   Relapsed Cancer Intervention :   Diagnostic Test: Molecular profiling and drug testing Sponsors :   Sydney Children's Hospitals Network;   Children's Cancer Institute Australia;   Australia and New Zealand Children's Haematology and Oncology Group (ANZCHOG);   Garvan Institute of Medical Research;   German Cancer Research Center (DKFZ) Recruiting

      Read Full Article
    11. Prognostic value of metabolic indices and bone marrow uptake pattern on preoperative 18F-FDG PET/CT in pediatric patients with neuroblastoma.

      Prognostic value of metabolic indices and bone marrow uptake pattern on preoperative 18F-FDG PET/CT in pediatric patients with neuroblastoma.

      Eur J Nucl Med Mol Imaging. 2017 Nov 07;:

      Authors: Li C, Zhang J, Chen S, Huang S, Wu S, Zhang L, Zhang F, Wang H

      Read Full Article
    12. Correlation of Somatostatin Receptor-2 Expression with Gallium-68-DOTA-TATE Uptake in Neuroblastoma Xenograft Models.

      Correlation of Somatostatin Receptor-2 Expression with Gallium-68-DOTA-TATE Uptake in Neuroblastoma Xenograft Models.

      Contrast Media Mol Imaging. 2017;2017:9481276

      Authors: Zhang L, Vines DC, Scollard DA, McKee T, Komal T, Ganguly M, Do T, Wu B, Alexander N, Vali R, Shammas A, Besanger T, Baruchel S

      Read Full Article
      Mentions: Imaging MIBG
    13. Structural and functional differences in phox2b frameshift mutations underlie isolated or syndromic congenital central hypoventilation syndrome.

      Structural and functional differences in phox2b frameshift mutations underlie isolated or syndromic congenital central hypoventilation syndrome.

      Hum Mutat. 2017 Nov 02;:

      Authors: Di Lascio S, Benfante R, Di Zanni E, Cardani S, Adamo A, Fornasari D, Ceccherini I, Bachetti T

      Read Full Article
      Mentions: PHOX2B
    14. Lin28B and miR-142-3p regulate neuronal differentiation by modulating Staufen1 expression.

      Lin28B and miR-142-3p regulate neuronal differentiation by modulating Staufen1 expression.

      Cell Death Differ. 2017 Nov 03;:

      Authors: Oh Y, Park J, Kim JI, Chang MY, Lee SH, Cho YH, Hwang J

      Abstract Staufen1 (STAU1) and Lin28B are RNA-binding proteins that are involved in neuronal differentiation as a function of post-transcriptional regulation. STAU1 triggers post-transcriptional regulation, including mRNA export, mRNA relocation, translation and mRNA decay.

      Read Full Article
    15. Health-related quality of life and psychological distress in young adult survivors of childhood cancer and their association with treatment, education, and demographic factors.

      Health-related quality of life and psychological distress in young adult survivors of childhood cancer and their association with treatment, education, and demographic factors.

      Qual Life Res. 2017 Oct 31;:

      Authors: Halvorsen JF, Sund AM, Zeltzer L, Ådnanes M, Jensberg H, Eikemo TA, Lund B, Hjemdal O, Reinfjell T

      Read Full Article
      Mentions: Treatment
    16. Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment.

      Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment.

      Neoplasia. 2017 Oct 26;19(12):982-990

      Authors: Rosswog C, Schmidt R, Oberthuer A, Juraeva D, Brors B, Engesser A, Kahlert Y, Volland R, Bartenhagen C, Simon T, Berthold F, Hero B, Faldum A, Fischer M

      Read Full Article
      Mentions: MYCN
    17. The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors.

      The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors.

      Pathol Oncol Res. 2017 Oct 28;:

      Authors: Felkai L, Bánusz R, Kovalszky I, Sápi Z, Garami M, Papp G, Karászi K, Varga E, Csóka M

      Abstract Soft tissue sarcomas (STS) and neuroblastomas (NBL), are childhood malignancies still associated with poor prognoses despite the overall improvement in childhood tumor survival of the past decades.

      Read Full Article
      Mentions: Treatment ALK
    18. Novel Mechanisms of ALK Activation Revealed by Analysis of the Y1278S Neuroblastoma Mutation.

      Novel Mechanisms of ALK Activation Revealed by Analysis of the Y1278S Neuroblastoma Mutation.

      Cancers (Basel). 2017 Oct 30;9(11):

      Authors: Guan J, Yamazaki Y, Chand D, van Dijk JR, Ruuth K, Palmer RH, Hallberg B

      Abstract Numerous mutations have been observed in the Anaplastic Lymphoma Kinase (ALK) receptor tyrosine kinase (RTK) in both germline and sporadic neuroblastoma.

      Read Full Article
      Mentions: ALK
    1-24 of 2798 1 2 3 4 ... 115 116 117 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. INBRACED

    See all INBRACED articles
  4. Organizations in the News

    1. (86 articles) COG
    2. (23 articles) NANT
    3. (22 articles) SIOP
    4. (19 articles) SIOPEN
    5. (18 articles) MSKCC
    6. (15 articles) INRG
    7. (15 articles) GPOH
    8. (11 articles) NMTRC
  5. Locations in the News

    1. (8 articles) Other Countries
  6. Researches in the News

    1. (231 articles) MYCN
    2. (204 articles) Immunotherapy
    3. (134 articles) Antibody
    4. (111 articles) ALK
    5. (84 articles) Imaging
    6. (75 articles) T-Cells
    7. (59 articles) Bone Marrow
    8. (47 articles) Metastasis
    9. (46 articles) ASCO
    10. (29 articles) PD-1
  7. General Informations in the News

    1. (400 articles) Treatment
    2. (24 articles) Staging
    3. (6 articles) Hearing Loss
  8. Treatments in the News

    1. (100 articles) Surgery
    2. (88 articles) Chemotherapy
    3. (86 articles) Refractory
    4. (78 articles) MIBG
    5. (67 articles) Stem Cell Transplant
    6. (63 articles) Relapse
    7. (60 articles) Radiotherapy
    8. (20 articles) Diagnostics
    9. (20 articles) Side Effects
    10. (9 articles) Targetted Therapy